Skip to main content
. 2022 Jun 27;9:870962. doi: 10.3389/fmed.2022.870962

Figure 4.

Figure 4

Changes in beta-cross laps values from the beginning of the study (time point 0) until the end of study (time point 5) for Placebo and PMA-treated patients. A separate representation for the patients enrolled as Placebo group at time point 0 (later treated with PMA-zeolite from time point 1–5) and enrolled patients treated with PMA-zeolite from the beginning of the study (time point 0–5) is given in the Supplementary Figure 1.